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VEGFstage of a broad range of disorders affecting organ function. These disorders are
often associated with aberrant angiogenesis, but whether vascular abnormalities during ﬁbrosis are
characterized by excessive or diminished neo-vascularization remains questionable. Strikingly, activation of
the coagulation cascade is frequently observed in association with the progression of ﬁbroproliferative
disorders. As we recently showed that coagulation factor (F)Xa induced ﬁbrotic responses in ﬁbroblasts, we
hypothesized that FXa might indirectly induce angiogenesis by triggering ﬁbroblasts to secrete proangiogenic
factors. In the present study, we show that although FXa induces p42/44 MAP Kinase phosphorylation in
endothelial cells, it has no direct effect on endothelial cell proliferation, protein synthesis and tube formation.
In contrast, conditioned medium of ﬁbroblasts stimulated with FXa enhanced endothelial cell proliferation,
extra cellular matrix synthesis, wound healing and endothelial tube formation. FXa induced VEGF production
by ﬁbroblasts and a VEGF neutralizing antibody blocked the indirect effect of FXa on proliferation and
realignment of endothelial cells identifying VEGF as a crucial player in angiogenesis during coagulation
factor-induced ﬁbrosis. Overall, our results establish a link between the coagulation cascade and angiogenesis
during ﬁbrosis.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionFibrotic disease constitutes the end-stage of a broad range of
pathologies affecting organ function [1]. Fibrosis might occur in many
differentorgans, but ismost commonly observed in the skin [2], liver [3],
lung [4], kidney [5] and heart [6]. At the cellular level, ﬁbrosis involves
aberrant ﬁbroblast proliferation and accumulation of extracellular
matrix (ECM) impairing normal organ function. Strikingly, activation
of the coagulation cascade is frequently observed in associationwith the
progression of ﬁbroproliferative disorders. For instance, post-ischaemic
renal damage is associatedwith ﬁbrin deposition [7].Moreover, alveolar
ﬁbrin deposition after acute lung injury leads to accelerated pulmonary
ﬁbrosis [8]. Physiologically, activation of the coagulation cascade is
initiated when vascular injury exposes tissue factor (TF) to the
circulating blood. Upon such vascular injury, TF is exposed to the
bloodallowingcomplex formationwith circulating (activated) factor (F)
VII (FVIIa). The TF/FVIIa complex in turn activates FX into FXa. FXa
converts prothrombin into thrombin which in turn cleaves ﬁbrinogen
into ﬁbrin, leading to the formation of a clot [9].
A mechanistic link between activation of the coagulation cascade
and the progression of ﬁbrosis is provided by the ability of activated
coagulation factors to proteolytically cleave and activate protease-31 206977192.
nsztajn).
ll rights reserved.activated receptors (PARs), a familyofG-protein-coupled receptors. Four
PARs (PAR-1 to -4), of which PAR-1, PAR-3 and PAR-4 can be activated by
thrombin, have been identiﬁed so far. The TF/FVIIa complex can activate
PAR-2 only, and FXa is able to activate PAR-1 and PAR-2 [10]. The role of
thrombin in ﬁbrotic processes has been extensively studied in vitro
[11–14], and thrombin signaling via PAR-1 plays indeed a crucial role in
the progression of ﬁbrosis [15,16]. Recently, we and others showed that
FXa also triggers ﬁbro-proliferative responses in ﬁbroblasts and smooth
muscle (SM) cells. FXa enhanced cell proliferation and migration, it
induced the secretion of pro-ﬁbrotic and pro-inﬂammatory cytokines
and stimulated ECM deposition [17–22].
Increasing evidence suggests that vascular endothelial growth
factor (VEGF) is a major regulator of ﬁbrosis and tissue remodeling
(like for instance asthma) [23,24]. Generally, ﬁbroblasts of the
connective tissue produce very low levels of VEGF but during ﬁbrosis
activated ﬁbroblasts secrete increased VEGF levels [25]. VEGF is a
potent angiogenic protein [26] involved in the formation of new
capillary blood vessels by a sequence of complex and precisely
programmed events that include proliferation and migration of
endothelial cells (ECs) into the surrounding tissue, the reconstruction
of a matrix and the assembly of ECs into capillary tubes [27].
Angiogenesis is instrumental during embryogenesis, tissue repair
after injury and the female reproductive cycle: indeed, even if during
adulthood most blood vessels remain quiescent, ECs retain their
remarkable ability to rapidly divide in response to physiological
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disbalance between pro- and anti-angiogenic factors is intrinsically
linked to disease progression. For instance, regression of angiogenesis
contributes to the progression from adaptive cardiac hypertrophy to
heart failure [28]. Also, in women with preeclampsia, increased levels
of anti-angiogenic proteins are identiﬁed in the placenta [29,30] and
serum [30–33]. In contrast, aberrant neo-angiogenesis is well known
to be responsible for tumor growth and metastasis [34,35].
The associations between modulation of angiogenesis and the
progression of the heterogeneous group of ﬁbrotic diseases are
numerous and very complex. Numerous studies report changes in
VEGF production and consequently in the density of the vascular
network during ﬁbrosis but contradictory both regression and/or
expansion of the vasculature has been observed. For instance, during
idiopathic pulmonary ﬁbrosis (IPF) both increased [36–40] and
decreased VEGF levels have been observed [41,42]. Also with respect
to vascular density, both increases [43–45] and decreases [45,46]
within ﬁbrotic lesions of IPF patients have been observed. Overall,
these studies pinpoint VEGF as a crucial player in angiogenesis during
ﬁbrosis. However, whether regression or proliferation of the vascular
network is a cause or consequence of ﬁbrosis remains elusive.
Consequently, it also remains questionable whether angiogenesis
accompanying ﬁbrosis is beneﬁcial of deleterious. Further elucidation
of the molecular mechanisms modulating VEGF production is there-
fore of critical importance for understanding the relationship between
angiogenesis and ﬁbrosis.
Next to its role in ﬁbrosis, the coagulation cascade is well-known to
be a crucial regulator of angiogenesis [47], and the role of individual
coagulation factors in angiogenesis has been especially studied during
the progression of cancer. For instance, TF/FVIIa and thrombin both
induce angiogenesis during cancer progression [35,48,49]. In contrast,
FXa does not seem to affect angiogenesis as, for instance, it does not
promote tube formation in vitro [50]. Interestingly, we recently
showed that FXa induced ﬁbro-proliferative responses in ﬁbroblasts,
whereas it has also been shown that FXa, but not thrombin or the
TF/FVIIa complex, induced VEGF release by human lung ﬁbroblasts
[20]. Consequently, we hypothesized that FXa might indirectly induce
angiogenesis by triggering ﬁbroblasts to secrete pro-angiogenic
factors thereby establishing a link between activation of the coagula-
tion cascade, angiogenesis and ﬁbrosis. To prove or refute this
hypothesis, we transferred medium of FXa-stimulated ﬁbroblasts to
endothelial cells, and examined the consequences on cell viability,
protein synthesis and tube formation.
2. Materials and methods
2.1. Cell lines, cell culture and reagents
The murine endothelial cells 2H11 and the murine ﬁbroblast cell
lines C2C12 and C3H10T1/2 were purchased from American Type
Culture Collection (ATCC, Manassas, VA), and maintained in Dulbec-
co's minimal essential media (DMEM) supplemented with 10% FCS
according to routine procedures. Unless speciﬁed otherwise, cells
werewashed twice with phosphate-buffered saline (PBS), then serum
starved overnight or for 4 h for 2H11 and C2C12 or C3H10T1/2
respectively prior to stimulation. Human FXa was obtained from
Kordia (Leiden, the Netherlands). VEGF-A blocking antibody (aVEGF)
was obtained from R&D Systems (Minneapolis, MN).
2.2. Preparation of conditioned media (CMs)
Murine ﬁbroblasts were grown in DMEM in the presence of 10%
FCS until 70–80% conﬂuence. The growth mediumwas then removed,
cell layers were washed twice with PBS and cells were cultured for
48 h in either serum-free medium supplemented with PBS (CM) or
174 nM FXa (CM FXa). Fibroblast-conditioned media were centrifugedat 14,000 rpm for 15 min, ﬁltered through 0.22 μM ﬁlters and stored
at −20 °C until use.
2.3. Western blot
Cells were lysed in Laemmli lysis buffer, incubated for 5min at 95 °C,
and whole cell lysates were separated by 10% SDS-PAGE. After
electrophoresis, proteins were transferred onto immobilon-P PVDF
membranes (Millipore, Billerica, MA). Membranes were incubated
overnight at 4 °C with primary antibodies to β-actin, MMP-9, MMP-2,
ICAM-1, VEGF-A, ﬁbronectin (all Santa Cruz, CA) and p42/44 MAP
Kinase (total and phosphor-speciﬁc; Cell Signaling Technology (Beverly,
MA)) in TBS with 0.1% Tween (TBS-T)/1% BSA. All secondary HRP-
conjugated antibodies were from DakoCytomation (Glostrup, Den-
mark). Blots were imaged using Lumilight Plus ECL substrate (Roche,
Basel, Switzerland) on aGeneGnome imager (Syngene, Cambridge, UK).
2.4. Viability assay (MTT)
104 cells per well were seeded onto 96-well plates in DMEM
supplemented with 1% FCS, and were treated with FXa (174 nM) or
PBS as control. To determine the effect of the conditioned media
(CMs) on cell viability, cells were seeded directly in the different CMs.
Cell viability was determined at the indicated intervals using a MTT
assay as described previously [51].
2.5. Anoikis
To induce anoikis, cells were plated in the different CMs on culture
plates coated with polyHEMA (10 mg/ml). At the indicated time
points, cells were harvested and viability was determined by MTT
assays.
2.6. Wound scratch assay
Wound scratch assays were performed as described previously
[21]. Brieﬂy, cells were plated in six-well plates and maintained in
DMEM supplemented with 10% FCS. After the cells reached 80 to 90%
conﬂuence, a wound was created in the center of the cell monolayer
by a sterile plastic pipette tip. Immediately thereafter, the cells were
washed with PBS to remove ﬂoating cellular debris and re-incubated
for an additional 24 h with CM or CM FXa. The ability of cells to
proliferate andmigrate into thewound areawas assessed after 24 h by
comparing the zero and 24 h phase-contrast micrographs of at least 3
marked points along the wounded area at each plate. The percentage
of non-recovered wound area was calculated by dividing the non
recovered area after 24 h by the initial wound area at zero time.
2.7. Endothelial cell morphogenesis assay
Murine endothelial cells (5⁎104) were resuspended in 0.3 ml of
the indicated medium, and plated on 24-well plates pre-coated with
growth factor-reduced (GFR)Matrigel (0.15ml). After 16 h at 37 °C/5%
CO2, each well was examined for endothelial cells alignment using a
phase contrast microscope. For quantiﬁcation of endothelial tube
formation, the number of tubes was counted in each well by blindly
scoring (by two independent investigators) at least 7 different ﬁelds
were by two observers.
2.8. RNA isolation and MLPA procedure
After 0–8 h of the indicated treatment, total RNAwas isolated using
Trizol (Invitrogen, Carlsbad, CA) according to manufacturer's recom-
mendation. Next, 100 ng total RNA was used for the MLPA reaction as
described previously [52,53]. Brieﬂy, MLPA is a multiplex ligation-
dependent ampliﬁcation procedure (RT-MLPA), which accurately
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throughput in combination with the limited amount of RNA necessary
makesMLPA an ideal technique to screen for gene expression changes in
a predeﬁned pathway. In the current study, the following genes were
analyzed: Apaf, Apaf-Xl, Bad, Bak, Bax-1, Bax-2, Puma, Bcl-2, Bcl-2A1,
Bcl-Xl, Bim, Bcl-W, Bcl-G, Bcl-Rambo, Bid, Bik, NIAP, IAP1, IAP2, XIAP,
Survivin, Apollon, Livin, Bmf, NIP-3, NIX, Flip, FLT, HRK, MAP1, Mcl1-S,
Mcl1-L, PARN, AIF, Noxa, GUS, PI-9 and Diablo.
2.9. Statistical analysis
The data are expressed asmean±standard error and Student's t test
is used to determine signiﬁcance (Pb0.05 was considered signiﬁcant).
3. Results
3.1. FXa induces phosphorylation of p42/44 MAP kinase in
endothelial cells
It is well known that endothelial cells express both PAR-1 and
PAR-2 [54] and FXa might thus inﬂuence angiogenesis through direct
PAR-mediated signaling in endothelial cells. As p42/44 MAP Kinase
phosphorylation is a downstream target of PAR cleavage [55], ECs
were either stimulated with 174 nM FXa (as this concentration is
commonly used to decipher the signaling effects of FXa in vitro
[21,51,56,57]) for 0–60min or for 30minwith different concentrations
of FXa. Subsequently, the activation of p42/p44 MAP kinase was
determined using western blotting. As evident from Fig. 1A, FXa
induces a time- (left panel) and concentration- (right panel)
dependent activation of p42/p44 MAP kinase. FXa has thus the
potential to directly induce signal transduction in ECs.
3.2. FXa has no direct effect on the angiogenic phenotype of
endothelial cells
Angiogenesis is associated with EC proliferation, EC realignment to
form tubes or lumen-like structures, and ECM synthesis. Hence, we
determined the effect of FXa on the proliferation of endothelial cells.
Cellswere incubated for 0 to 48 hwith 174 nMFXa, as this concentration
had a maximal effect on cell signaling or with PBS and cell viability was
determined at the indicated time points. As shown in Fig.1B, FXa did notFig. 1. FXa has no direct effect on the angiogenic phenotype of ECs. (A) FXa induces direct sig
or for 30 min with 0–174 nM FXa (right panel). Cell lysates were assayed for western blot for
signaling has no functional consequence on EC survival. Serum-starved ECs were incubated
using MTTassays. Shown are the results of a representative experiment, which was repeated
effect on EC alignment. ECs (5⁎104) were resuspended in serum-free medium, supplemente
and methods section. Shown are representative pictures of an experiment which has beensigniﬁcantlymodify EC viability. Next, we determined the direct effect of
FXa on the synthesis of ECM proteins or matrix-degradation proteases.
FXa did not induce the expression of ﬁbronectin or matrix metallopro-
teinase (MMP) -2 and -9 (which are crucial proteins of angiogenesis) by
endothelial cells (data not shown). Finally, FXa did not modify
endothelial cell realignment or reorganization in tubes (Fig. 1C). Thus,
although FXa does induce intracellular signaling in ECs, it does not
markedly inﬂuence their angiogenic phenotype.
3.3. CM FXa enhances viability of ECs and stimulates tube formation
As FXa had no direct functional consequences on endothelial cells,
we next assessedwhether FXamightmodify angiogenesis indirectly via
activation of ﬁbroblasts. To this end, CM collected from C3H10T1/2
ﬁbroblasts stimulated with FXa (CM FXa) was compared to CM of PBS-
treated ﬁbroblasts for its angiogenic properties. We ﬁrst compared the
effect of both CMs on EC survival. Cells were seeded directly in CM or
CM FXa and cell viability was measured at the indicated time points. As
shown in Fig. 2A, CM FXa enhanced viability by 168±4.5% after 48 h
(P=0.0002), whereas CM did not have this effect (105±1.5%). The
same results were observed with CM FXa prepared from C2C12
ﬁbroblasts (data not shown). During angiogenesis, ECs need to detach
from the ECM to migrate and therefore need to survive without
attachment (anoikis) during this period. Therefore, 96-well plates were
coated with poly-HEMA and EC viability was determined. As shown in
Fig. 2B, loss of adhesion rapidly affected cell viability. However, CM FXa
signiﬁcantly enhanced cell viability after 2 h by 116.1±5.2% (P=0.028)
as compared to CM. The same results were observed with CM FXa
prepared from C2C12 ﬁbroblasts (data not shown). Next, we deter-
mined the effect of CM FXa on ECM protein synthesis. To this end, ECs
seeded in CM and CM FXa were assayed for ﬁbronectin synthesis.
Indeed, CM FXa enhanced ﬁbronectin production, whereas CM did not
induce ﬁbronectin production (Fig. 2C). Both CM FXa as well as CM did
not induce MMP-2/-9 synthesis (data not shown).
We next assessed the effect of the different CMs onwound closure,
which involves both proliferation and migration. As shown in Fig. 2D,
CM had no effect on the size of the wound, whereas CM FXa signi-
ﬁcantly induced wound healing as evident from the reduced wound
size. Finally, we explored whether CM FXa provoked the alignment of
endothelial cells or the formation of lumen-like structures. As shown
in Fig. 2E, ECs incubated in CM FXa aligned to form lumen-likenaling in ECs. Quiescent ECs were stimulated for 0–60 minwith 174 nM FXa (left panel),
p42/44 phosphorylation using total p42/44 as loading control. (B) FXa-induced direct
for 0–48 h with 174 nM FXa, or PBS as a negative control. Cell survival was determined
3 times in octuplicate with similar results. Values are mean±SEM. (C) FXa has no direct
d with PBS (C neg) or with FXa, and plated onto Matrigel as described in the Materials
performed 3 times with similar results.
Fig. 2. CM FXa induces a pro-angiogenic phenotype in ECs. (A) CM FXa promotes EC proliferation. Survival of ECs seeded in CM or CM FXawas determined usingMTTassays. Shown is
the mean±SEM of 5 different experiments performed in octuplicate. ⁎⁎⁎Pb0.001. (B) CM FXa inhibits anoikis. ECs resuspended in CM or CM FXa were seeded in plates coated with
poly-HEMA. Cell survival was determined at the indicated time points using MTT assays. Shown is the mean±SEM of 2 different experiments performed in septuplicate. ⁎Pb0.05 (C)
CM FXa enhances ﬁbronectin secretion by ECs. ECs seeded in CM or CM FXa for 24 h were lysed and lysates were used for western blot to determine ﬁbronectin expression. Actin
served as loading control. Shown is a representative picture of an experiment performed three times with similar results. (D) CM FXa enhances wound closure in ECs. Wound size of
ECs treated with CM or CM FXawas analyzed 24 h after wounding the endothelial monolayer as described in Materials and methods section. Shown is the mean±SEM of 2 different
experiments performed in triplicate. ⁎⁎Pb0.005. (E) CM FXa promotes endothelial tube formation. ECs (5⁎104) were resuspended either in CM or in CM FXa and plated on Matrigel
as described in Materials and methods. After 16 h, tube formation was assessed. (Top panel) Representative pictures of an experiment performed 3 times. (Bottom panel)
quantiﬁcation of tube formation. Show is the mean±SEM of 3 different experiments. ⁎⁎Pb0.005.
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Quantiﬁcation showed that CM FXa enhanced tube formation by
185±16.8% (P=0.0013) as compared to control CM. This capillary-
like network of ECs induced by CM FXa appears to be less organized
than that induced by conditioned medium obtained from ﬁbroblasts
cultured with 10% FCS (data not shown), possibly suggesting a
relatively disorganized angiogenesis. The same results were observed
with CM FXa prepared from C2C12 ﬁbroblasts (data not shown). Since
we showed that FXa had no direct effect on endothelial cell survival,
realignment or protein synthesis, these results strongly suggest that
the observed effects of CM FXa on angiogenesis are not due to FXa
present in the CMs but rather that FXa exerts a powerful indirect pro-
angiogenic effect through the activation of ﬁbroblasts.
3.4. Characterization of the anti-apoptotic effect exerted by CM FXa
As indicated above, CM FXa enhanced viability and alignment of
endothelial cells. To assess whether this is due to modiﬁcations in the
apoptotic balance induced by CM FXa, we performed MLPA geneexpression analysis. To this end, RNA isolated from endothelial cells
stimulated for 8 h with CM FXa or CM prepared from C3H10T1/2
ﬁbroblasts was isolated. To determine possible direct effects of FXa on
the mRNA levels, ECs were incubated for the same period in serum-
free medium (SF) or serum-free medium containing 174 nM of FXa.
Through expression proﬁling of 39 genes involved in apoptosis using
MLPA, we observed that a single anti-apoptotic gene was induced by
CM FXa. CM FXa induced expression of the anti-apoptotic protein
Bcl-2 (induction of 183±35% (P=0.002)) as compared to the ECs
stimulated with CM (Fig. 3A). Importantly, ECs stimulated with FXa
directly did not modify the expression of this anti-apoptotic gene
(Fig. 3B), which is in line with the absence of a direct effect of FXa on
endothelial cell survival (Fig. 1B).
3.5. FXa induces a pro-angiogenic phenotype in ﬁbroblasts through
VEGF expression
The pro-angiogenic effect of CM FXa on ECs implies that FXa
induces the release of a pro-angiogenic factor by ﬁbroblast responsible
Fig. 3. CM FXa enhances the expression of Bcl-2 in ECs. ECs were serum-starved overnight after which the serum-free medium was replaced by CM or CM FXa (A), or serum-free
mediumwith (FXa) or without (SF) FXa. After 24 h incubation, mRNAwas isolated and assayed for expression of pro- and anti-apoptotic genes as described inMaterials and methods
section. On 37 genes analyzed, CM FXa only induced Bcl-2 expression.
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the most potent pro-angiogenic proteins, is synthesized in lung and
dermal ﬁbroblasts stimulated with coagulation factors VIIa, Xa and
thrombin [20,58], we focussed our attention on VEGF. First, we
veriﬁed that FXa induced the release of VEGF by C3H10T1/2 and
C2C12 ﬁbroblasts. Fibroblasts were incubated in serum-free medium
for 24 h with different concentrations of FXa. As shown in Fig. 4A for
C3H10T1/2 ﬁbroblasts, FXa induced VEGF synthesis in a concentra-
tion-dependent manner in both cell lysates and supernatants. Similar
results were observed for C2C12 cells (data not shown).
To determine the contribution of VEGF released by ﬁbroblasts to
the pro-angiogenic effect of FXa on endothelial cells, we added an
antibody that neutralizes the bio-activity of VEGF to CM and CM FXa.
As shown in Fig. 4B, CM FXa signiﬁcantly enhanced cell viability as
compared to CM (167.2±8.2%, P=0.0002), and this effect is
approximately 2-fold reduced in the presence of the VEGF blocking
antibody (from 167.2±8.2% to 134.7±8.5%; P=0.0047). Importantly,
the blocking antibody did not affect EC viability in CM (107.2±5.6%).Fig. 4. FXa-induced pro-angiogenic effects of ﬁbroblasts are mediated via VEGF productio
concentrations of FXa. Subsequently, supernatant was harvested and cells were lysed. Both s
served as loading control. Shown are representative pictures of an experiment done three ti
were seeded in the different conditioned media, with (white bars) or without (black bars) V
MTTassay. Shown is the mean±SEM of 2 different experiments. n.s.: non signiﬁcant,⁎Pb0.05
formation. ECs were seeded in the different conditioned media, with (white bars) or witho
formation was quantiﬁed as described in the Materials and methods section. Shown is theAs shown in Fig. 4C, CM FXa also signiﬁcantly promotes tube formation
(163.6±14%) as compared to CM. The addition of the VEGF blocking
antibody did not modify tube formation by CM (82.2±11.24%), but it
completely blocked CMFXa-induced tube formation (from163.6±14%
to 62±9.3%; P=0.0001). Hence, FXa-induced VEGF production by
ﬁbroblasts seems to account for the pro-angiogenic phenotype
resulting in proliferation and realignment of ECs.
4. Discussion
In the present study, we demonstrate that FXa induces an indirect
pro-angiogenic phenotype of ECs through activation of ﬁbroblasts.
Although FXa directly induced signaling in ECs, FXa had no direct
effect on EC proliferation and/or tube formation. This is in line with a
previous study [50], showing that FXa did not promote tube formation
in vitro. In contrast, CM FXa enhanced the viability of both adherent
cells and cells in anoikis likely via the expression of the anti-apoptotic
protein Bcl-2. Furthermore, CM FXa induced ECM synthesis (as shownn. (A) Quiescent C3H10T1/2 ﬁbroblasts were stimulated for 24 h with the indicated
upernatant and cell lysates were assayed by western blot for VEGF production. ICAM-1
mes with similar results. (B) Effect of a VEGF-neutralizing antibody on EC survival. ECs
EGF-neutralizing antibody. Cell viability was determined after 24 h incubation using an
, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.001. (C) Effect of a VEGF-neutralizing antibody on endothelial tube
ut (black bars) VEGF-neutralizing antibody, and plated onto Matrigel. After 16 h, tube
mean±SEM of 2 different experiments. n.s.: non signiﬁcant, ⁎⁎Pb0.005, ⁎⁎⁎Pb0.001.
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formation. The induction of these responses by CM FXa as compared
to CM suggested that FXa stimulated the secretion of one or more
growth factors by ﬁbroblasts. Indeed, FXa induced the secretion of
VEGF by ﬁbroblasts and a VEGF blocking antibody diminished the
effect of CM FXa on EC proliferation and tube formation.
Our results might be relevant for physiological wound healing but
more importantly they establish a link between activation of the
coagulation cascade, ﬁbrosis and aberrant angiogenesis. Indeed,
ﬁbroblasts are exposed to coagulation factors following vascular injury,
but activation of the coagulation cascade also occurs inmany pathologi-
cal conditions such as ﬁbrosis. In patients suffering from lung ﬁbrosis
for instance, thrombin levels and zymogen FX levels are increased and
these patients also represent with enhanced ﬁbrin deposition [8].
Alternatively, FXa may be secreted by macrophages at sites of inﬂam-
mation, or FXa may leak into the connective tissue from the vascular
compartment as a result of chronic activation of the coagulation
cascade, after extensive and continued endothelial injury [59].
Recent data suggest that FXa plays an important role in ﬁbrotic
processes. As opposed to TF/FVIIa and thrombin, FXa activates PAR-2
thereby eliciting various and complex signaling events. We and others
showed that, in ﬁbroblasts, FXa induces the synthesis of ECM proteins
such as ﬁbronectin and collagen [17,21]. FXa also stimulated
ﬁbroproliferative responses in ﬁbroblasts and induced ﬁbroblast
differentiation into myoﬁbroblasts [21]. Here, we demonstrate that
the responses induced by FXa on ﬁbroblasts also modify the
angiogenic balance, thereby establishing a link between activation of
the coagulation cascade, the progression of ﬁbrosis and the induction
of angiogenesis. Interestingly, our data show that FXa-induced
signaling is not redundant of TF/VFIIa and/or thrombin signaling as
the latter coagulation factors directly induce angiogenic effects on
endothelial cells via PAR-1 activation [35,48,49]. FXamight does play a
dual role in angiogenesis. Via its procoagulant effects, FXa induces
thrombin formationwhich on its turn directlymodiﬁes the angiogenic
phenotype of endothelial cells. Through its signaling properties
however, FXa activates ﬁbroblasts (in a PAR-2 dependent manner
[60]), to secrete VEGF thereby indirectly affecting the endothelium.
Chronic ﬁbroproliferative disorders are associated with aberrant
angiogenesis, but the exact underlying mechanism is still elusive
[61,62]. An important outstanding question is whether the primary
vascular abnormality during ﬁbrosis is actually excessive or dimi-
nished neo-vascularization [62]. Consequently, the role of angiogen-
esis (beneﬁcial versus harmful) and the effect of modiﬁcations to the
VEGF balance during ﬁbrosis remain questionable. Three hypotheses
have been put-forward however. Based on observations that attenu-
ating vascular remodeling is associated with reduced pulmonary
ﬁbrosis in animal models [36–40], it was postulated that angiogenesis
contributes to the progression of ﬁbrosis. Another hypothesis emerged
from the results of studies showing that both VEGF levels [41,42] and
vascular density are decreased within ﬁbrotic lesions as compared to
non-ﬁbrotic regions [43–46]. In a murine model of interstitial renal
ﬁbrosis, decreased vascular density was associated with renal
impairment, whereas infusion of VEGF improved renal function and
decreased interstitial renal ﬁbrosis [63,64]. Moreover, VEGF gene
transfer in rabbits results in reduction of bleomycin-induced pulmo-
nary hypertension, suggesting a protective effect [65]. Based on these
observations it is suggested that angiogenesis limits or counteracts
ﬁbrosis. Finally, it has been suggested that aberrant angiogenesis
accompanying ﬁbrosis is just an epiphenomenon and thus not play a
physiological role [62]. Our present study supports the hypothesis that
ﬁbrosis causes angiogenesis, implying that angiogenesis is not only a
passive bystander during ﬁbrosis. Whether this (indirect) induction of
angiogenesis by FXa is beneﬁcial or deleterious during ﬁbrosis is
obviously impossible to predict based on our current data. One could
argue that FXa generation resulting in ﬁbroblast proliferation and
VEGF release subsequently inducing angiogenesis might be beneﬁcialfor the restoration of tissue function during ﬁbrosis (as discussed in
[66]). However, it is noteworthy that VEGF has proﬁbrotic and
ﬁbroproliferative effects [67–70] and might thus aggravate ﬁbrosis.
Recently, it was shown that during airway remodeling (which shares
common features with ﬁbrotic disease like, among others, coagulation
cascade activation, exaggerated ﬁbroblast proliferation and ECM
deposition) in asthmatic patients, VEGF up-regulates thrombin levels,
which in turn enhances bFGF release thereby amplify the ﬁbrotic
process. This latter notion that FXa-induced angiogenesis would be
deleterious in pulmonary ﬁbrosis is supported by recent data showing
that inhibition of coagulation signiﬁcantly reduced bleomycine-
induced ﬁbrosis [15]. Although not targeting FXa speciﬁcally, these
data suggest that inhibiting coagulation-induced angiogenesis is
beneﬁcial. In agreement, low molecular weight heparin (dalteparin;
FXa inhibitor with some residual thrombin inhibition) treatment of
patients with idiopathic pulmonary ﬁbrosis had a beneﬁcial effect on
survival [71]. Overall, these data suggests that FXa-induced angioge-
nesis is detrimental in ﬁbrosis although future in vivo experiments
should conﬁrm this hypothesis.
Obviously, one should keep in mind that angiogenesis is a
complicated multi-step process. All individual steps are obviously
not solely orchestrated by VEGF, and angiogenesis is the result of
cooperation between VEGF and other angiogenic factors which must
collaborate in perfect harmony to form functional vessels. Different
models of vascular formation have shown that VEGF initiates the
formation of vessels by vasculogenesis or angiogenic sprouting while
other angiogenic factors, such as angiopoietins, are required for
further remodeling and maturation of this initially immature
vasculature [61]. Angiopoietins regulate angiogenesis by activating
or blocking the activation of Tie-2, a surface receptor tyrosine kinase
generally restricted to endothelial cells. Especially, angiopoietin-2
(ang-2) is expressed in areas undergoing vascular remodeling and is
involved in neovascularization. It has been proposed that in the
presence of VEGF, Ang-2 may maintain the endothelium in a more
plastic state [72]. Whether FXa alsomodulates the expression of ang-2
by ﬁbroblasts, or the expression of the VEGF receptor and/or Tie-2 by
endothelial cells (as been shown for thrombin [73]), is currently not
known.
Induction of a pro-angiogenic phenotype by coagulation factor
induced-signaling in ﬁbroblasts might also be of importance in other
pathological conditions. For instance, many epithelial tumors are
characterized by the local accumulation of myoﬁbroblasts in the
stroma reaction (i.e. local ﬁbrosis associated with malignant tumors
[74]). Myoﬁbroblasts control tumor angiogenesis by creating a pro-
angiogenic microenvironment thereby facilitating EC recruitment, as
shown in [75] for melanoma cells. Thus, differentiation of ﬁbroblasts
into myoﬁbroblasts by FXa [21] and/or thrombin [76] subsequently
inducing angiogenesis might be an additional link between activation
of the coagulation cascade and disease progression.
Overall, the release of pro-angiogenic factors by FXa-stimulated
ﬁbroblasts may link the coagulation cascade to vascular remodeling
during ﬁbrosis. Obviously, this conclusion is based on in vitro data only
and the in vivo relevance of our ﬁndings needs further assessment.
Future studies aiming at a detailed in vivo understanding of the
interplay between activation of the coagulation cascade, the progres-
sion of ﬁbrosis and the role of angiogenesis in these processes are
needed to establish the importance of our ﬁndings.
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